Correction: Accessibility to molecular studies in gliomas: a challenge for precision medicine in low-resource countries - Top-Institutions - MDSpire

Correction: Accessibility to molecular studies in gliomas: a challenge for precision medicine in low-resource countries

  • By

  • Pablo S. Paolinelli

  • Tomas Saavedra Azcona

  • Florencia BCasto

  • Ezequiel Jungberg

  • Nicolás Tilano

  • William ABlettler

  • Joan SPazos

  • Silvina Dell’Era

  • Clara Lynch

  • Miguel Villaescusa

  • Pedro Plou

  • Pablo Ajler

  • June 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas M.D. Anderson Cancer Center
    University of Texas M.D. Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Neuro-Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Neuro-Oncology

  • #3

    University of California, Los Angeles
    University of California, Los Angeles

    Los Angeles, California

    Key Differentiators

    • Oncology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #5

    University of Maryland, Baltimore
    University of Maryland, Baltimore

    Baltimore, Maryland

    Key Differentiators

    • Oncology

Original Source(s)

Correction: Accessibility to molecular studies in gliomas: a challenge for precision medicine in low-resource countries

  • by Pablo S. Paolinelli, Tomas Saavedra Azcona, Florencia BCasto, Ezequiel Jungberg, Nicolás Tilano, William ABlettler, Joan SPazos, Silvina Dell’Era, Clara Lynch, Miguel Villaescusa, Pedro Plou, Pablo Ajler

  • June 9, 2026

Related Content

Editorial: New Insights on Sialic Acid and Sialylated Glycans in the Tumorigenic Process

This Week’s CGT News: Promising Data for In Vivo CAR T

Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts

  • June 8, 2026

  • 6 min
Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement